WO2004091546A3 - Combinaison d'un stimulateur du systeme nerveux central et d'antagonistes d'opiates - Google Patents
Combinaison d'un stimulateur du systeme nerveux central et d'antagonistes d'opiates Download PDFInfo
- Publication number
- WO2004091546A3 WO2004091546A3 PCT/US2004/009161 US2004009161W WO2004091546A3 WO 2004091546 A3 WO2004091546 A3 WO 2004091546A3 US 2004009161 W US2004009161 W US 2004009161W WO 2004091546 A3 WO2004091546 A3 WO 2004091546A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- opioid antagonist
- nervous system
- central nervous
- system stimulant
- antagonist combinations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US45894003P | 2003-03-31 | 2003-03-31 | |
US60/458,940 | 2003-03-31 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2004091546A2 WO2004091546A2 (fr) | 2004-10-28 |
WO2004091546A3 true WO2004091546A3 (fr) | 2005-03-24 |
Family
ID=33299655
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2004/009161 WO2004091546A2 (fr) | 2003-03-31 | 2004-03-25 | Combinaison d'un stimulateur du systeme nerveux central et d'antagonistes d'opiates |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2004091546A2 (fr) |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE102005033543A1 (de) * | 2005-07-14 | 2007-01-18 | Grünenthal GmbH | Ein einen Duftstoff aufweisendes transdermales therapeutisches System |
DE102006015734A1 (de) * | 2006-04-04 | 2007-10-11 | Hermann, Holger Lars, Dr. | Kombinationspräparate aus Modafinil, Ritalin und Topiramat und deren Derivaten zur Behandlung von Kokainabhängigkeit und/oder Impulskontrollstörung |
FR2899476B1 (fr) * | 2006-04-11 | 2008-07-04 | Assist Publ Hopitaux De Paris | Association du mazindol dans le traitement du deficit de l'attention/hyperactivite |
DE102007024428A1 (de) * | 2007-05-25 | 2008-11-27 | Hermann, Holger Lars, Dr. med. | Verwendung von Naloxon als Abususschutz bei Nicht-Opioiden und Nicht-Opiaten |
US20120302590A1 (en) | 2009-08-13 | 2012-11-29 | The General Hospital Corporation | Methods and compositions to prevent addiction |
EP3324975B1 (fr) * | 2015-07-22 | 2022-05-18 | John Hsu | Composition comprenant un agent thérapeutique et un stimulant respiratoire, et procédé d'utilisation associé |
WO2022251683A1 (fr) * | 2021-05-27 | 2022-12-01 | Allen Gregory Seth | Formulation pour perte de poids et procédés |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5604198A (en) * | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
-
2004
- 2004-03-25 WO PCT/US2004/009161 patent/WO2004091546A2/fr active Application Filing
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968551A (en) * | 1991-12-24 | 1999-10-19 | Purdue Pharma L.P. | Orally administrable opioid formulations having extended duration of effect |
US5604198A (en) * | 1994-05-12 | 1997-02-18 | Poduslo; Joseph F. | Method to enhance permeability of the blood/brain blood/nerve barriers to therapeutic agents |
Also Published As
Publication number | Publication date |
---|---|
WO2004091546A2 (fr) | 2004-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003252478A1 (en) | Ccr4 antagonist and medicinal use thereof | |
AU2003302603A1 (en) | Improved opioid pharmaceutical compositions | |
HUP0401191A3 (en) | Opioid agonist formulations with releasable and sequestered antagonist and process for their preparation | |
AU2003272601B2 (en) | Sustained-release opioid formulations and methods of use | |
PL376373A1 (en) | Selected cgrp antagonists, method for production and use thereof as medicament | |
IL175260A0 (en) | Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors | |
HK1072559A1 (en) | Methods and dosage forms for controled delivery ofpaliperidone | |
AP2002002617A0 (en) | Tamper-resistant oral opioid agonist formulation | |
LT2425821T (lt) | Farmacinis preparatas, turintis oksikodono ir naloksono | |
AU2003220205A1 (en) | Ethanol-diesel fuel composition and methods thereof | |
HK1080471A1 (en) | Secondary amino anilinic piperidines as mch1 antagonists and uses thereof | |
IL175292A0 (en) | Pharmaceutical composition, containing a beta-3- adrenoceptor agonist and an alpha antagonist and/or a 5-alpha-reductase inhibitor | |
ZA991745B (en) | Combination of a selective NMDA NR2B antagonist and an opioid analgesic. | |
AU2001251083A1 (en) | Method for using 2-aryloxyalkylaminobenzoxazoles and 2-aryloxyalkylaminobenzothiazoles as h3 antagonists | |
PL353613A1 (en) | Application of oestrogen agonist/antagonist in production of a drug | |
AU2003277215A1 (en) | Novel neurokinin antagonists and methods of use thereof | |
MY143499A (en) | Crf receptor antagonist and methods relating thereto | |
WO2004091546A3 (fr) | Combinaison d'un stimulateur du systeme nerveux central et d'antagonistes d'opiates | |
AU2001239356A1 (en) | Method for hydrogenating nitrile functions into amine functions | |
AU2003274789A1 (en) | Handheld terminal, system and method for managing golf scores | |
AU2002352388A1 (en) | N-aroyl cyclic amine derivatives and their use as orxin receptor antagonist | |
AU2002368487A1 (en) | Substituted 1,4-di-piperidin-4-yl-piperazine derivatives and their use as tachykinin antagonists | |
AU5404500A (en) | Reductive amination of aldehydes | |
AU2003272349A8 (en) | Enantioselective amination and etherification | |
IL175293A0 (en) | Pharmaceutical formulation containing an ltb4 antagonist, method for the production thereof, and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
122 | Ep: pct application non-entry in european phase |